Key Insights Natera's estimated fair value is US$101 based on 2 Stage Free Cash Flow to Equity Current share price of...
AUSTIN, Texas, September 23, 2024--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today issued the following statement regarding its ongoing patent infringement litigation with NeoGenomics in response to inquiries:
Parnassus Investments, an investment management company, released the “Parnassus Growth Equity Fund” second quarter 2024 investor letter. A copy of the letter can be downloaded here. In the second quarter, the Fund (Investor Shares) returned 3.74% (net of fees) underperforming the Russell 1000 Growth Index’s 8.33%. Stock selection in the Information Technology sector primarily drove the […]